Skip to main content
SpringerLink
Log in

Dauerhafte Heilung bei vielen Patienten

Das ist neu in der Therapie der Hepatitis C

The news in hepatitis C therapy

  • FORTBILDUNG . ÜBERSICHT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Zusammenfassung

Die Einführung der neuen direkt antiviral wirksamen Medikamente hat die Therapie der chronischen Hepatitis C revolutioniert. Dank dieser Entwicklung sind wir heute in der Lage, den überwiegenden Teil unserer Hepatitis-C-Patienten dauerhaft zu heilen. Für die tägliche Praxis ist daher eine gezielte Diagnostik bezüglich einer Hepatitis C von großer Bedeutung, um infizierte Patienten identifizieren und behandeln zu können.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Webster DP, Klenermann P et al. Hepatitis C. Lancet. 2015;385:1124–35

    Article  PubMed  PubMed Central  Google Scholar 

  2. Blachier M, Leleu H et al. The burden of liver disease in Europe: A review of available epidemiological data. J Hepatol. 2013;58:593–608

    Article  PubMed  Google Scholar 

  3. Robert-Koch-Institut. Epidemiologisches Bulletin Nr. 29, 25. Juli 2016

  4. Thein HH, Yi Q, Dore GJ, Krahn MD: Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008;48:418–31

    Article  PubMed  Google Scholar 

  5. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76

    Article  CAS  PubMed  Google Scholar 

  6. Ramos-Casals M, Zignego AL et al. Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. J Hepatol. 2017;66:1282–99

    Article  PubMed  Google Scholar 

  7. Smith DB, Bukh J et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014;59:318–27

    Article  PubMed  Google Scholar 

  8. Messina JP, Humphreys I et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61:77–87

    Article  PubMed  Google Scholar 

  9. Hüppe D, Zehnter E et al. Epidemiology of chronic hepatitis C in Germany - an analysis of 10,326 patients in hepatitis centres and outpatient units. Z Gastroenterol. 2008;46:34–44

    Article  PubMed  Google Scholar 

  10. De Luca A, Di Giambenedetto S et al. Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors. Open Forum Infect Dis. 2015;2 - https://doi.org/10.1093/ofid/ofv043

  11. Zimmermann R, Marcus U et al. A multicentre sero-behavioural survey for hepatitis B and C, HIV and HTLV among people who inject drugs in Germany using respondent driven sampling. BMC Public Health. 2014;14:845

    Article  PubMed  PubMed Central  Google Scholar 

  12. Schmidt AJ, Rockstroh JK et al. Trouble with bleeding: risk factors for acute hepatitis C among HIV-positive gay men from Germany — a case-control study. PloS one 2011;6:e17781

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Jansen K, Thamm M et al. High Prevalence and High Incidence of Coinfection with Hepatitis B, Hepatitis C, and Syphilis and Low Rate of Effective Vaccination against Hepatitis B in HIV-Positive Men Who Have Sex with Men with Known Date of HIV Seroconversion in Germany. PLoS One 2015;10:e0142515

    Article  PubMed  PubMed Central  Google Scholar 

  14. Hagan H, Jordan AE et al. Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men. Aids. 2015;29:2335–45

    Article  PubMed  PubMed Central  Google Scholar 

  15. McFaul K, Maghlaoui A et al. Acute hepatitis C infection in HIV-negative men who have sex with men. J Viral Hepat. 2015;22:535–8

    Article  CAS  PubMed  Google Scholar 

  16. Sarrazin C, Berg T et al. Prophylaxis, Diagnosis and Therapy of Hepatitis C Virus (HCV) Infection: The German Guidelines on the Management of HCV Infection. Z Gastroenterol. 2010;48:289–351

    Article  CAS  PubMed  Google Scholar 

  17. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63:237–264

  18. Zeuzem S. Treatment options in hepatitis C — the current state of the art. Dtsch Arztebl Int. 2017;114:11–21

    PubMed  PubMed Central  Google Scholar 

  19. Lange CM, Jacobson IM et al. Emerging therapies for the treatment of hepatitis C. EMBO Mol Med. 2014;6:4–15

    Article  CAS  PubMed  Google Scholar 

  20. Sarrazin C, Hézode C et al. Antiviral strategies in hepatitis C virus infection. J Hepatol. 2012;56(Suppl 1):88–100

    Article  Google Scholar 

  21. Aktuelle Empfehlungen zur Therapie der chronischen Hepatitis C. www.dgvs.de/wissen-kompakt/leitlinien/leitlinien-der-dgvs/hepatitis-c

  22. Ioannou GN, Beste LA et al. Effectiveness of Sofosbuvir,Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens forTreatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System. Gastroenterology 2016;151:457–71

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Bruno S, Stroffolini T et al. Sustained virologhical response to interfreron-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45:579–87

    Article  CAS  PubMed  Google Scholar 

  24. Van der Meer AL, Veldt BJ et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis c and advanced hepatic fibrosis. JAMA. 2012;308:2584–93

    Article  PubMed  Google Scholar 

  25. Kowdley KV, Gordon SC et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–88

    Article  PubMed  Google Scholar 

  26. Ferenci P, Bernstein D et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983–92

    Article  PubMed  Google Scholar 

  27. Welzel TM, Asselah T et al. Lancet Gastroenterol Hepatol. 2017 Apr 13. pii: S2468-1253(17)30071 7. doi: 10.1016/S2468-1253(17) 30071-7 (Epub ahead of print)

  28. Zeuzem S, Ghalib R et al. Grazoprevir-Elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients withchronic hepatitis C virus genotype 1, 4, or 6 infection: A randomizedtrial. Ann Intern Med. 2015;163:1–13

    Article  PubMed  Google Scholar 

  29. Zeuzem S, Dusheiko GM et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370:1993–2001

    Article  PubMed  Google Scholar 

  30. Feld JJ, Jacobson IM et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373:2599–607

    Article  CAS  PubMed  Google Scholar 

  31. Foster GR, Afdhal N et al. Sofosbuvir and Velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373:2608–17

    Article  CAS  PubMed  Google Scholar 

  32. Sulkowski MS, Gardiner DF et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211–21

    Article  CAS  PubMed  Google Scholar 

  33. Bourlière M, Gordon SC et al. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med. 2017;376:2134–46

    Article  PubMed  Google Scholar 

  34. Jacobson IM, Lawitz E et al. Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. Gastroenterology. 2017;153:113–22

    Article  CAS  PubMed  Google Scholar 

  35. Forns X, Lee SS et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 2017;14. pii: S1473–3099(17)30496–6

    Google Scholar 

  36. Kwo PY, Poordad F et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017;67:263–71

    Article  CAS  PubMed  Google Scholar 

  37. Poordad F, Felizarta F et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology. 2017;66:389–97

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Zeppelinstraße 16, D-89160, Dornstadt, Deutschland

    Nektarios Dikopoulos

  2. Klinik für Innere Medizin I, Universitätsklinikum Ulm, Ulm, Deutschland

    Johanna Backhus

  3. Klinikum Landshut, Medizinische Klinik I, Landshut, Deutschland

    Matthias Dollinger

Authors
  1. Nektarios Dikopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Johanna Backhus
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthias Dollinger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nektarios Dikopoulos.

Additional information

This article is part of a supplement not sponsored by the industry.

INTERESSENKONFLIKTE

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen. Sie legen folgende potenzielle Interessenkonflikte offen: Frau Dr. Backhus: Vortragshonorar der Firma Gilead; Prof. Dikopoulos: Vortragshonorare der Firmen Gilead, AbbVie und MSD. Prof. Dollinger: Vortrags- und Beratertätigkeit sowie Studiendurchführung für die Firmen Gilead, AbbVie, Merck, BMS und Janssen.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dikopoulos, N., Backhus, J. & Dollinger, M. Das ist neu in der Therapie der Hepatitis C. MMW - Fortschritte der Medizin 159 (Suppl 3), 43–52 (2017). https://doi.org/10.1007/s15006-017-9595-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-017-9595-4

Keywords

Search

Navigation